[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406522-105":59,"doc-detail-406522-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","combinational-therapy-with-myc-decoy-oligodeoxynucleotides-encapsulated-in-nanocarrier-and-x-irradiation-on-breast-cancer-cells","Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells","","The Myc gene is a key oncogene in triple-negative breast cancer (TNBC). This study evaluates synergistic anticancer effects by combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation on the MDA-MB-468 breast cancer cell line. Myc decoy and scramble ODNs were designed from Bcl2 promoter sequences and loaded into chitosan to form Chi-Se-DEC, then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/combinational-therapy-with-myc-decoy-oligodeoxynucleotides-encapsulated-in-nanocarrier-and-x-irradiation-on-breast-cancer-cells/406522/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/combinational-therapy-with-myc-decoy-oligodeoxynucleotides-encapsulated-in-nanocarrier-and-x-irradiation-on-breast-cancer-cells/406522.png","ImageObject",300,407,{"name":92,"@type":93},"Muffet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main therapeutic strategy tested in this study?","Question",{"text":113,"@type":114},"The study tests a combinational approach pairing Myc decoy oligodeoxynucleotides-encapsulated hybrid nanocarriers with X-irradiation for improved anticancer effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which breast cancer cell line was used?",{"text":118,"@type":114},"The experiments were performed on the MDA-MB-468 cell line.",{"name":120,"@type":111,"acceptedAnswer":121},"How was the nanocarrier constructed and characterized?",{"text":122,"@type":114},"Myc ODNs and selenium were loaded into chitosan (Chi-Se-DEC) and encapsulated into niosomes (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were used to confirm characterization and physicochemical properties.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},406522,1790822169,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962090768927,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","ONCOLOGY RESEARCH 2024 32(2): 309-323  \nCombinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells  \nBEHROOZ JOHARI 1,2,\\#,*; MILAD PARVINZAD LEILAN 1,\\#; MAHMOUD GHARBAVI3; YOUSEF MORTAZAVI 1; ALI SHARAFI2; HAMED REZAEEJAM4  \n1 Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran  \n2 Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran  \n3 Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  \n4 Department of Radiology Technology, School of Allied Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran  \nKey words: Combinational therapy, Antisense therapy, Myc signaling pathway, Niosomes, Radiation therapy, SeNPs  \nAbstract: The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC) . This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC) . FT-IR, DLS, FESEM, and hemolysis tests were applied to confirm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell cycle, and scratch repair assays were performed to evaluate its anticancer effects on cancer cells. All anticancer assessments were repeated under X-ray irradiation conditions (fractionated 2Gy) . Physicochemical characteristics of niosomes containing SeNPs and ODNs showed that it is synthesized appropriately. It revealed that the anticancer effect of NISM@Chi-Se-DEC can be significantly improved in combination with X-ray irradiation treatment. It can be concluded that NISM@Chi-Se-DEC nanocarriers have the potential as a therapeutic agent for cancer treatment, particularly in combination with radiation therapy and in-vivo experiments are necessary to confirm the efficacy of  \nthis nano-drug.  \nList of Abbreviations  \nSeNPs Selenium nanoparticles  \nBSA Bovine serum albumin  \nChi Chitosan  \nBC Breast cancer  \nBCSCs Breast cancer stem cells  \nTNBC Triple-negative breast cancer  \nEDC 1-(3-dimethylaminopropyl)-3-ethylcarbodii  \nmide hydrochloride NHS N-hydroxysuccinimide  \nCy3 Cyanine-3  \n*Address correspondence to: Behrooz Johari, [Behroozjohari@yahoo.com](Behroozjohari@yahoo.com), [Dr.johari@zums.ac.ir](Dr.johari@zums.ac.ir)  \n\\#Behrooz Johari and Milad Parvinzad Leilan contributed equally to this work and hence are co-first authors  \nReceived: 06 July 2023; Accepted: 13 October 2023;  \nPublished: 28 December 2023  \nSe Selenium  \nODNs Oligodeoxynucleotides  \nSCR Scrambled  \nTFD Transcription factor decoy  \nPS Phosphorothioate  \nPDI Polydispersity Index  \nDLS Dynamic light scattering  \nFT-IR Fourier transform infrared  \nTEM Transmission electron microscope  \nSDS Sodium dodecyl sulfate  \nPI Propidium iodide  \nIntroduction  \nTriple-negative breast cancer is a subtype of breast cancer where cancer cells lack the human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and  \nDoi: [10.32604/or.2023.043576 www.techscience.com/journal/or](10.32604/or.2023.043576 www.techscience.com/journal/or)  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \n310 BEHROOZ JOHARI et al.  \nprogesterone receptor (PR) [1,2] . The treatment of TNBC is challenging because these cells are very invasive and cause early metastasis [3] . Common approaches to treating breast cancer include surgery, hormo","cbCaiisxVbTeJnet","https://ap.wps.com/l/cbCaiisxVbTeJnet","pdf",46937807,15,"English","# Key findings\n## Experimental design and cell model\n## Nanocarrier characterization\n## Cellular assays and combined treatment","[{\"question\":\"What is the main therapeutic strategy tested in this study?\",\"answer\":\"The study tests a combinational approach pairing Myc decoy oligodeoxynucleotides-encapsulated hybrid nanocarriers with X-irradiation for improved anticancer effects.\"},{\"question\":\"Which breast cancer cell line was used?\",\"answer\":\"The experiments were performed on the MDA-MB-468 cell line.\"},{\"question\":\"How was the nanocarrier constructed and characterized?\",\"answer\":\"Myc ODNs and selenium were loaded into chitosan (Chi-Se-DEC) and encapsulated into niosomes (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were used to confirm characterization and physicochemical properties.\"}]","Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells | PDF",1790566220,38]